From the start of next year onwards, Jacob Tolstrup will lead Lundbeck's sales and marketing activities across all of the pharmaceutical company's business areas when he takes on the role of chief commercial officer (CCO), the company reveals in a press release.
Peter Anastasiou, executive vice president for North America, has decided to leave the post at the end of the year to pursue another opportunity, the press release reports, meaning that Tolstrup can take on this market alongside the markets in the rest of the world, which he is already responsible for. Anastasiou has been the person responsible for the launch of migraine drug Vyepti.
Already a subscriber? Log in.
Read the whole article
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.